Drug Trial Radar · NCT06854458
The Multicenter Stress Cardiac Magnetic Resonance Quantitative Perfusion Imaging in the United States Study
Last checked: Nov 19, 2026Latest source record: Sep 1, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
1,000
Planned (sponsor's estimate)
Start
Jun 27, 2025
Primary completion
Jan 2029
Study completion Mar 2029
Sponsor
- Lead sponsor
- Brigham and Women's HospitalAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Mar 3, 2025
Design
- Study type
- Interventional
- Phase
- Not applicable
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Diagnostic
- FDA-regulated drug
- No
- Who can join
- All sexes, from 35 years, up to 85 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This research aims to investigate whether symptoms of chest pain or shortness of breath among the study population are arising due to a heart problem, particularly any reduction of blood flow to the heart muscle from blockages in the coronary blood vessels or inflammation of the heart using cardiac magnetic resonance imaging that measures the amount of blood flow during a stress state meant to simulate vigorous exercise. At present, doctors use standard magnetic resonance imaging pictures of blood flow patterns to treat heart disease. The investigators want to study if detailed blood flow measurements, in addition to the standard blood flow pattern, could diagnose heart disease more accurately and allow more doctors to understand the severity of heart disease. Early research has demonstrated that detailed blood flow measurements may be more accurate in diagnosing heart disease in some patients, but doctors need more information to know how to use these measurements.
Conditions
- Ischemic Heart Disease (IHD)
- Cardiac Magnetic Resonance Imaging
- Myocardial Blood Flow
Interventions
Quantitative Myocardial Blood Flow EvaluationDiagnostic test
The perfusion sequence will produce on-the-fly additional quantitative perfusion maps with segmental myocardial blood flow values.
Qualitative Myocardial Blood Flow EvaluationDiagnostic test
The perfusion sequence will not produce additional quantitative perfusion maps.
GadavistDrug
Participants will receive Gadavist 0.05 mmol/kg dose for each stress and rest perfusion imaging (total dose of 0.1 mmol/kg).
VasodilatorDrug
All participants will receive vasodilator (regadenoson or adenosine depending on local site practice).
Blood draw for the laboratory assessmentDiagnostic test
A single (7-10 ml tube) whole blood sample will be collected from each patient for processing of blood biomarkers.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Primary composite outcome of major cardiovascular adverse events (MACE)Time frame: From cardiac magnetic resonance imaging to the end of follow-up in 24 months
Locations
13 sites in 1 country. Site status is shown where the registry gives one.
University of California San Francisco
San Francisco, California · Recruiting
UofL Health - Heart Hospital
Louisville, Kentucky · Recruiting
Brigham and Women's Hospital
Boston, Massachusetts · Recruiting
Beth Israel Deaconess Medical Center
Boston, Massachusetts · Recruiting
St. Francis Hospital and Heart Center
Roslyn, New York · Recruiting
Atrium Health - Sanger Heart & Vascular Institute
Charlotte, North Carolina · Recruiting
Cleveland Clinic
Cleveland, Ohio · Recruiting
The Ohio State University
Columbus, Ohio · Recruiting
Vanderbilt University Medical Center
Nashville, Tennessee · Recruiting
Houston Methodist Hospital
Houston, Texas · Recruiting
University of Utah
Salt Lake City, Utah · Recruiting
University of Virginia
Charlottesville, Virginia · Recruiting
Virginia Commonwealth University
Richmond, Virginia · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.